Search
Anthralin
go.drugbank.com/drugs/DB11157ApprovedIt is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not been observed with this anthralin, in contrast to a wide variety of systemic and topical … Salicylic acid is frequently added to anthralin to augment the stability of anthralin and to increase its penetration and efficacy [L1979].
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigational[A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. … It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name
Cinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalFirst synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness. … Cinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting
Levocabastine
go.drugbank.com/drugs/DB01106ApprovedLevocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
Categories: Histamine H1 Antagonists, Non-SedatingTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours. … Tisotumab vedotin targets TF-expressing cells to deliver MMAE to induce direct cytotoxicity and bystander killing of neighboring cells.
Propiverine
go.drugbank.com/drugs/DB12278ApprovedOveractive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the night to urinate) … OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents [L2327], [L2328].
Products: MICTONORM UNO 30MG, MICTONORM UNO 45MGErenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalAimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the … Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines
Polyvinyl alcohol
go.drugbank.com/drugs/DB11060ApprovedPolyvinyl alcohol is a water-soluble synthetic polymer obtained by polymerization of vinyl alcohol. … Polyvinyl alcohol is found in ophthalmic solutions as a lubricant to prevent irritation or to relieve dryness of the eyes [L2826].
Nadroparin
go.drugbank.com/drugs/DB08813ApprovedInvestigationalWithdrawnNadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. … Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.